 hard ware get better lower estim rais target price
lower estim target price factor coffe price eros weak start
soliri biosimilar risk bark bite revis estim rais target price
food thought boeing/safran apu ventur anoth harbing thing come
portol-huh posit cerdulatinib data asco overshadow ceo retir
mayb knockout keytruda remain heavyweight i-o champion
forecast bcf build week end june
household chang net worth
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
cs view highlight recent initi repres highli differenti treasur hunt format
uniqu quick store return profil signific white space opportun comparison difficult fy
continu focu sale growth come new store drive top bottom-lin growth
estim estim ep fy vs prior line consensu pace
comp modestli street anticip difficult april weather like impact repres
easiest comparison year start lap high-single-digit comp driven fidget
spinner trend fy neg comp wide anticip look quarter-to-d comp
commentari key indic call
 hard ware get better lower estim rais target price
pre-announc headlin metric friday fulli report result morn includ robust
guidanc clear outgo ceo mark mclaughlin leadership continu out-execut
competit scale benefit sever cyclic tailwind
guidanc guid ahead expect bill product total revenu total revenu rais
midpoint revenu beat nearli driven increas product
guidanc impli increas servic guidanc remain origin outlook provid
begin year believ minor increas reflect acquisit secdo evid io see second
consecut impli servic guide-down given conserv acquisit estim
conclud overachiev larg hardware-refresh-driven and/or unattach subscript under-perform
result product revenu bill well ahead cs/street servic in-lin dollar base new bill
durat remain broadli constant quarter year result durat adjust bill growth
report substanti reacceler albeit vs easi y/i compar adj growth gm
y/i due mix lower-gm new hardwar pressur product gm note management disclos
discount actual better y/i q/q oper incom expect impact drag
acquir expens new employe ad
season high end guid rang impli well histor season trend howev note
strongest season sinc bill product result extrem challeng q/q
valuat new dcf-deriv tp repres non-gaap price-to-earnings ntm vs chkp/ftnt
 upsid risk target price includ better attach subscript growth includ cloud/virtu lower
ep estim respect
receiv product pleas specifi credit suiss contact email call
lower estim target price factor coffe price eros weak start
lower ep estim reiter ep estim well
consensu due concern around declin price power coffe vulner pet food
portfolio estim anoth downsid fy estim earn dilut smucker execut plan
sell pillsburi bake busi lower target price
busi result appear deceler may base nielsen track data expect sale growth
deceler compar achiev retail sale ground coffe pet treat bake product
dog food deceler quarter uncrust single-serv coffe peanut butter remain strong initi
inventori load new folger coffe might provid upsid estim think product recal
subsequ discontinu wet gravi train dog food sale off-set benefit price
sale declin folger coffe past week profit undercut bull case coffe
busi benefit fall coffe input cost
valuat target price assum forward ev/ebitda multipl ebitda estim
assum discount packag food peer roughli in-lin histor averag think discount
justifi smucker brand becom increasingli commodit rebound coffe margin repres
soliri biosimilar risk bark bite revis estim rais target price
overhang share resolut either support upsid two focal point recent
convers investor global switch strategi viabl given soliri eu ip uncertainti
drive lt growth expect partial full resolut first overhang investor recogn
biosimilar risk may larg limit pnh indic lacklust competit data far probabl biosimilar
pushout suggest bearish timelin assumpt low risk like allow ampl time convert market
soliri less convict lt growth question believ meaning acquisit necessari fulli
address issu note highli competit landscap present good-fit asset
climb wall worri absenc clear catalyst share volatil within rang ytd despit
posit data strong soliri gmg launch step toward revamp pipelin singular
event consid major valuat driver think constel move closer filing/approv market
recognit ahus/gmg protect base price advantag soliri orphan statu solid probabl
delay biosimilar launch timelin potenti new soliri ip issuanc oral proceed schedul feb-
support higher price earli
biosimilar impact seem overst substanti uncertainti biosimilar timelin base model assum
blend probabl scenario assign eu/row launch stress model realist worst-cas
time eu/row biosimilar launch modest impact appli max stress scenario
launch new patient soliri share biosimilar still yield valuat higher current share
valuat rais tp acceler convers assumpt within year
launch decreas competit assumpt risk relat commerci franchis revis
ep estim respect
receiv product pleas specifi credit suiss contact email call
food thought boeing/safran apu ventur anoth harbing thing come
monday jv news safran yet anoth remind structur chang impos
aerospac suppli chain effort rais profit lower cyclic captur aftermarket key precursor
therefor captur oe content aftermarket-en ip high level see three-phas
process today disrupt newsflow phase valuat impact impact phase aftermarket
sale profit traction oe expens supplier equilibrium phase competit respons
new-entr oem leverag technolog disenfranchis former ba supplier expand market share
first uncov new approach april wrote year note rewrit
rule follow deep dive winter come essenti leadership began recogn
leav profit tabl follow decades-old convent relinquish aftermarket opportun supplier
return assumpt develop expens compon new aircraft past ba prefer
reli subcontractor labor-intens compon avoid expens touch labor book given
recent improv labor-sav autom ba target key compon area wing avion
propuls system interior actuat believ insourc yield profit aftermarket stream
look back even street caught less obviou action promot strategi perhap
initi catalyst undertaken entir differ reason solv product delay acquisit
integr vought global aeronautica fabric oper charleston sc possibl
remind ba proper manag autom insourc certain activ would prove less tax
believ prior manufactur gener
bottom line report cc estimate note re-affirmed neg pre
expect rev/ep rev/ep guidanc in-line
updat street adj expect flat q/q season q/q driven
double-digit q/q growth wire storag industrial/auto off-set
q/q declin wireless well season q/q expect q/q
season q/q driven wireless q/q season q/q see upward
bia ep gm lower wireless mix lower s/o buy-back author expect
wireless double-digit y/i de-risk addit wire y/i see
reacceler y/i posit catalyst lastli expect rais quarterli
div oct consist target ttm drive dividend yield amongst
highest sector
wireless de-risk adj expect wireless q/q vs season q/q
q/q vs season q/q despit y/i content increas new sku subdu unit
less favor mix impact see current estim de-risk unit potenti share loss
wire reacceler wire y/i adjust extra week see wire y/i
rebound y/i addit check continu support strong ramp tomahawk
jericho qumran mix shift toward wire wireless multipl accret
strong risk/reward opm hit target ep upsid driven share would struggl even w/o
distract under-perform ppt sinc ev/fcf disc peer expect
div hike bn buy-back wire reacceler wireless de-risk one best
receiv product pleas specifi credit suiss contact email call
announc shell portfolio win monday morn announc agreement issu oper shell
full portfolio commerci fleet card unit state canada begin august deal give
shell full privat label small fleet revolv small/mid-s fleet navig larg fleet portfolio us
win share posit announc show strategi keep invest platform
help compani win share meet demand larg nation client portfolio competit win
citi estim ep impact like immateri mark second larg portfolio loss
announc decemb
roll-out smooth believ shell agreement could similar size deal
estim rang forecast revenu howev shell transit expect
smoother current cardhold sent new card old card expir transit
extend sever quarter portfolio transit proven complic
financi impact believ implement transit cost could drive higher expens may
limit ep accret year estim full run-rat busi could gener increment ep
though could split
postal servic rfp catalyst believ winner usp rfp mail carrier fleet card like
announc come month deadlin transit decemb believ could win portfolio well
current oper voyag
upbeat market remain upbeat regard end market demand despit investor concern
sustain fact china construct market concern demand strong
ee market well normal level european construct prior peak mine larger custom
still bought look replac equip start extend besid
onshor north america ga compress market normal level us construct high
end ten-year trend line sign overh
umplebi initi pay renew focu oper excel oe drive alloc greater
resourc product line higher opacc oppt drive better decis make account
construct furthest along regard oe success evid margin wherea
resourc still middl inning strateg also focus grow servic capabl particular
construct under-penetrated view margin target laid
analyst day sept market still well normal level believ revisit/rais target
point provid posit catalyst stock
stori traction believ capit alloc messag disappoint ep call new
cfo start septemb provid oppt announc larg repurchas program believ
repurchas grow dividend two like outcom major view larger would
tougher get past hurdl line given new management return focus market lead posit key prod
line instead would look bolt-on anyth round prod offerings/increas content well continu
invest technolog
receiv product pleas specifi credit suiss contact email call
portol-huh posit cerdulatinib data asco overshadow ceo retir
bottom line two big announc yesterday though one expect first present
posit data syk/jak inhibitor cerdulatinib today preview note
abstract releas stock trade lower open potenti follow press releas mention five patient
death trial poster discuss present stock slowli ralli back
friday close price stock fell light trade hour compani announc retir
detail ceo retir spoke current cfo co-interim presid mardi dier even learn
detail behind surpris announc follow call left impress
spontan decis anybodi involv compani reiter timelin like look extern
new ceo success background launch new product emerg biotech compani await
detail appoint comfort may turn long-term posit move even may
lead near-term weak share
cerdulatinib data encourag present data today cerdulatinib varieti non-hodgkin lymphoma
five patient death interestingli highlight press releas specif call poster
mainli arm plan move forward though data earli show compel
respons rate includ complet respons three indic advanc clinic ctcl fl
provid valid reason believ drug potenti bring upsid time
heavi duti order larg medium duti releas later may class preliminari order came
unit vs expect order sequenti rel last year
worth note month season adjust begin inflect posit may adjust class order
unit year-to-d class order total unit averag per month larg driven
signific order seen first three month year cool april elev expect
look ahead posit strong trucker profit continu support strong order believ
use equip market need care monitor given signific amount trade-in return
market term expect order look ahead low thirti season
weak low twenti medium duti order releas act research later date
receiv product pleas specifi credit suiss contact email call
part seri review individu small group rate file review rate file new york washington
rhode island made avail last week analysi rate file state see note
earli individu rate file show va md ca find rate file bcb vt find
individu sg rate file review common theme emerg
ny individu small group market rate request averag rate increas request includ impact
individu mandat repeal fourteen health insur submit ny individu market particip includ
impact individu mandat repeal request rate updat vari y/i declin healthnow new
york y/i increas fide fide rate increas request compar
increas compani receiv fide current control largest market share ny individu
market enrol roughli qualifi health plan qhp live essenti plan ep live nineteen health
insur submit ny small group market particip request rate updat vari y/i declin
healthnow new york y/i increas healthfirst
trend assumpt major ny insur individu market fide attribut high rate increas four
assumpt reduc enrol statewid individu product expens annual
medic claim trend annual pharmaci claim trend blend trend assumpt
regulatori chang risk-shar pool increas premium rate prior experi fide
rate request includ premium increas relat elimin individu mandat penalti empir
assum medical/rx cost trend price excellu assum blend trend
driven increas medic increas pharmaci
washington state individu market file analysi eleven health insur file health plan washington state
individu famili health insur market averag propos rate increas
bare counti counti one insur sell washington exchang request rate increas
rang bridgespan kaiser among major insur coordin
corpor request rate increas vs request rate
increas vs approv
mayb knockout keytruda remain heavyweight i-o champion
keytruda remain king sat major well analyst event
even even comfort view top pick us pharma driven
expect increas use keytruda patient newli diagnos form metastat lung cancer
halo effect help increas keytruda traction indic well stock work way
see continu upsid ahead actual surpris degre weak share today
see path potenti recoveri time remain neutral rate given upcom catalyst calendar
get better sens pace see pressur line lung cancer sale note
analyst meet within note
make best list believ data present yesterday
impact data one compani quickli move keytruda becom standard care
patient tumor squamou histolog also give keytruda access line lung cancer
market overal surviv data compani express clear confid abl commerci product
success base well data present previous would argu data
realli sell also indirect impact keytruda use indic becom
choic lead upsid keytruda total estim
underwhelm patient receiv keytruda regardless thought data
yesterday could deliv potenti knockout blow competitor show clear role monotherapi keytruda
patient express level happen benefit driven patient pd-
express increas number patient group receiv keytruda combin
chemotherapi anyway base result trial howev sinc
combin approach could potenti get displac clearli superior combin futur although
expect happen meaning way least next year
receiv product pleas specifi credit suiss contact email call
forecast bcf build week end june
expect bcf build week end june forecast eia report bcf build work ga storag
level week end june bullish vs year-ago averag inject bcf bcf
respect estim inventori increas bcf widen deficit vs averag
bcf bcf respect
weather last week much warmer last year averag last week weather
warmer year-ago week averag respect cool degre day remain ahead us
project storag refil novemb last week withdraw impli weather-adjust s/d balanc
tighten slightli last month estim weather-adjust s/d bcfd oversuppli vs last
year bcfd oversuppli vs five-year averag forecast storag refil novemb bcf
year-ago averag head winter
receiv product pleas specifi credit suiss contact email call
headlin price previou day close unless otherwis note
compani mention price jun
